Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC

Affiliation auteurs!!!! Error affiliation !!!!
TitreFive-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC
Type de publicationJournal Article
Year of Publication2020
AuteursLind M., Gettinger S., Borghaei H., Brahmer J., Chow L., Burgio M., J. Carpeno DCastro, Pluzanski A., Arrieta O., O. Frontera A, Chiari R., Butts C., Wojcik-Tomaszewska J., Coudert B., Garassino M., Ready N., Felip E., M. Garcia A, Waterhouse D., Domine M., Barlesi F., Antonia S., Wohlleber M., Gerber D., Czyzewicz G., Spigel D., Crino L., Eberhardt W., Li A., Marimuthu S., Vokes E.
JournalLUNG CANCER
Volume139
PaginationS49-S50
Date PublishedJAN
Type of ArticleMeeting Abstract
ISSN0169-5002